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Act  (StZG)  











1. The Central Ethics Committee for Stem Cell Research 
 
The Central Ethics Committee for Stem Cell Research (ZES) is an independent, 
interdisciplinary expert body that reviews and assesses applications for the import and use of 
human embryonic stem cells (hES cells). The activities of the Committee are governed by 
the Act ensuring the protection of embryos in conjunction with the import and use of human 
embryonic stem cells (Stammzellgesetz – StZG) of 28 June 2002 (BGBl. I p. 2277, 
http://217.160.60.235/BGBL/bgbl1f/BGBl102042s 2277.pdf), amended by the Act amending 
the Stem Cell Act of 14 August 2008 (BGBl. I p. 1708, 
http://www.bgblportal.de/BGBL/bgbl1f/bgbl108s1708.pdf), and the Regulations concerning 
the Central Ethics Committee for Stem Cell Research and the competent authority pursuant 
to the Stem Cell Act (ZES-Verordnung – ZESV) of 18 July 2002 (BGBl. I p. 2663) 
(http://217.160.60.235/BGBL/bgbl1f/ bgbl102s2663.pdf).  
 
The Commission has a total of nine members from the fields of biology, medicine as well as 
philosophical, medical and theological ethics and nine deputy members from the 
corresponding disciplines (see Table 1). Both the members and the deputy members 
regularly participate in the deliberations on the applications pursuant to ZESV. The members 
and deputy members of ZES perform their duties on a voluntary basis. They were appointed 
for the first time with the entry into force of the Stem Cell Act on 1 July 2002 for three years 
by the Federal Government. The Committee is now engaged in its third term in office. 
 
The task of ZES to scientifically review applications for the import and use of hES cells for 
their ethical acceptability pursuant to § 5 StZG is specified in § 9 StZG. In each case it must 
be determined whether the use of hES cells applied for serves research purposes of superior 
interest for increased scientific knowledge (§ 5 No. 1 StZG), whether the required preliminary 
tests are available for the scientific questions (§ 5 No. 2a StZG) and whether the desired 
scientific knowledge can probably only be achieved with hES cells (§ 5 Nr. 2b StZG). Based 
on four votes by the members and deputy members on each application, ZES summarises 
the results in a written opinion. The opinion is given to the competent authority pursuant to 
StZG, the Robert Koch Institute (RKI).  
 
As consideration must be given to the latest natural scientific aspects in addition to ethical 
aspects when reviewing and assessing the applications submitted, the work of ZES requires 
the ongoing monitoring and consideration of the latest scientific developments in the field of 
stem cell research. During the reporting period the Committee once again took a 
comprehensive look at international standards for research on hES cells and monitored, 
more particularly, the development of research on human induced pluripotent stem cells 
(hiPS cells). Given their properties and their differentiation potential they are frequently 
examined in comparison with hES cells.  
 
ZES prepares an annual report which is published by the Federal Ministry of Health (BMG) (§ 
14 ZESV). The previous ZES reports can be accessed on the BMG website 
(www.bmg.bund.de) and the RKI website 
http://www.rki.de/cln_160/nn_207092/DE/Content/Gesund/Stammzellen/ZES/Taetigkeitsberi
chte/taetigkeitsbericht__node.html?__nnn=true). 






Table 1: Members and Deputy Members of the Central Ethics Committee for Stem Cell Research (ZES), status 
November 2009 
Field Member Deputy Member 
 
Prof. Dr. rer. nat. Hans R. Schöler 




Prof. Dr. rer. nat. Martin Zenke 
Institut für Biomedizinische Technologien 





Prof. Dr. rer. nat. Anna M. Wobus 
(Deputy Chairperson) 










Prof. Dr. phil. Ludwig Siep 
(Chairman) 
Philosophisches Seminar 
Westfälische Wilhelms-Universität Münster 
 
 
Prof. Dr. phil. Jan Beckmann 
Institut für Philosophie 
FernUniversität in Hagen 
Ethics 
 
Prof. Dr. med. Claudia Wiesemann 





Prof. Dr. med. Giovanni Maio, 
Institut für Ethik und Geschichte der Medizin 
Albert-Ludwigs-Universität Freiburg 
 
Prof. Dr. med. Gustav Steinhoff 
Klinik und Poliklinik für Herzchirurgie  
Universität Rostock  
 
 




Prof. Dr. med. Marion B. Kiechle 
(Deputy Chairperson) 
Frauenklinik und Poliklinik 
Klinikum rechts der Isar 
Technische Universität München 
 
 
Prof. Dr. med. Ricardo E. Felberbaum 
Frauenklinik 
Klinikum Kempten Oberallgäu 
Medicine 
 
Prof. Dr. med. Anthony D. Ho 
Med. Universitätsklinik und Poliklinik 




Prof. Dr. med. Ulf Rapp 





Prof. Dr. theol. Klaus Tanner 
Wissenschaftlich-Theologisches Seminar 




Prof. Dr. theol. Hartmut Kreß 
Evangelisch-Theologische Fakultät 







Prof. Dr. theol. Dr. phil. Antonio Autiero 
Seminar für Moraltheologie 
Katholisch-Theologische Fakultät 
Westfälische Wilhelms-Universität Münster 
 
Prof. Dr. theol. Konrad Hilpert 
Lehrstuhl für Moraltheologie 
Katholisch-theologische Fakultät 
Ludwig-Maximilians-Universität München 





2. Deliberation and review of applications pursuant to § 5 StZG during the 
reporting period  
 
During the reporting period ZES held seven meetings at which a total of 15 applications for 
the import and use of hES cells were extensively discussed. ZES has already handed down 
a positive opinion on 14 applications. These definitively approved projects meet the 
preconditions of § 5 StZG and are ethically acceptable within its intendment (§ 9 StZG). One 
application is still being deliberated. Another application, for which ZES had already handed 
down a positive opinion in the previous reporting period, was approved by RKI at the 
beginning of the new reporting period (in December 2008). As, pursuant to § 11 StZG, data 
on an application may only be published after its approval, this report only contains 
information on applications approved by RKI during the reporting period. Table 2 gives an 














Comparative characterisation of human adult 












Studies on the generation of artificial heart tissue 











Reprogramming of human somatic cells by 
defined factors and comparative studies of 
human induced pluripotent stem cells (hips cells) 
and human embryonic stem cells 
 
15.12.2008 
4 (38) Medizinische Hochschule 
Hannover 
 
Cultivation, characterisation and differentiation 
of human induced pluripotent stem cells 





Zentrum für Integrative 
Psychiatrie gGmbH, Kiel 
 
 
Studies on the pluripotency of human induced 
pluripotent stem cells and embryonic stem cells 
using whole genomic and proteomic 
approaches. Development of algorithms to 






molekulare Genetik, Berlin 
 
 
Comparative studies on the molecular basis of 
pluripotency and on the targeted differentiation 












Study on the immunological properties of human 










Prof. Dr. Agapios Sachinidis 




Optimisation of the cultivation and cardiac 








Studies on the biology of the retrotransposons of 







medizinische Technik (IBMT), 
St. Ingbert 
 
Optimisation of the cultivation and differentiation 
of human embryonic stem cells 
18.05.2009 
11 (45) Universitätsklinikum Essen 
 
Targeted differentiation of pluripotent human 
embryonic stem cells and induced pluripotent 








Analysis of the pancreatic differentiation of 
human embryonic stem cells and induced 
pluripotent cells for the purpose of studying the 




Prof. Dr. Jürgen Hescheler, 




Characterisation of the human T-cell leukemia 1 








Targeted differentiation of human embryonic 









In vitro reconstruction of human retina formation 
using human embryonic stem cells and their use 
in the transplantation of photoreceptor precursor 




Table 2: Overview of projects that were approved during the reporting period by RKI following a definitive, positive assessment 





In several of the research projects reviewed by ZES during the reporting period (Approvals 
35, 37, 38, 39, 40), hES cells are mainly used for comparative purposes for the 
characterisation and differentiation of pluripotent cells of diverse origin. In the first project 
(Approval 35) hES cells are to be compared with novel stem cells from human testicular 
tissue (human adult germline stem cells, haGSCs). The project seeks to provide answers to 
the questions about whether and, if so, to what extent human adult germline stem cells and 
hES cells have identical properties, whether their characteristics differ and the reasons for 
the possible differences. 
 
The third project (Approval 37) looks at new and improved strategies for the induction of 
pluripotency in somatic cells. hES cells are used firstly for a direct comparison of the 
properties of hiPS cells. Secondly, various stages of further differentiated cells of different 
cell types generated from the hES cells are themselves to undergo reprogramming. Here the 
goal is to gain better understanding of the molecular processes during reprogramming.  
 




The fourth project (Approval 38) is to undertake comparative studies of hES cells and hiPS 
cells, manufactured using different methods, in order to characterise the properties of both 
cell types on the levels of the transcriptome, epigenome and during early differentiation in 
conjunction with embryoid bodies and teratomes. The goal here is to test and establish the 
cultivation of these cells and their differentiation in larger volumes than on the laboratory 
scale. The studies likewise aim to help to elucidate functional commonalities or differences 
regarding the differentiation potential of both cell types into heart, lung and liver cells as well 
as cells of the haematopoietic line. The production of disease-specific human induced 
pluripotent stem cells of patients suffering from rare genetic lung diseases is planned in the 
longer term. 
 
The classification of hiPS cells, hES cells and also of their differentiated derivatives regarding 
the specific phenotype that is characteristic of pluripotent cells using total genomic and 
proteomic methods is the subject of the fifth project (Approval 39). It aims to undertake 
comparisons of both types of stem cells (hES cells versus hiPS cells) within various lines of 
the same pluripotent cell type, within the same stem cell line (e.g. after longer in vitro 
cultivation) and between various hiPS cells from the same cell source (e.g. hiPS cells from 
the same patient, that have been produced separately from one another). In addition, after 
the differentiation of hES cells into fibroblasts, neural cells and blood cells, a comparative 
study is to be undertaken of differentiated cells from various cell sources, and also of 
differentiated and non-differentiated cells.  
 
The comparative use of hES cells and hiPS cells for the analysis of molecular processes, 
which play a role in maintaining pluripotency, in triggering specific differentiation processes 
and in long-term cultivation, is the focus of the sixth project (Approval 40). It is a supplement 
to the ninth approval from 2005. The planned comparison of neurons that have been 
differentiated from various cell sources (from hiPS cells from Parkinson patients, healthy 
individuals and hES cells), seeks to improve the characterisation and understanding of 
neurodegenerative diseases. 
 
Approval 36 (second project) involves the continuation and stepping up of work conducted 
since 2005 with the approval of RKI. The goal is to establish effective protocols for the in vitro 
production of human heart tissue (Engineered Heart Tissue, EHT) from hES cells which 
could then be used as an in vitro heart muscle model and as a substitute for heart tissue. It 
also aims to create the foundations for an in vitro test system for reliably predicting the 
effects of medicinal products on heart cells. To this end, the transcriptome and proteome of 
the resulting heart cells are to be compared with hES cells. Furthermore, the factors involved 
in cardiac differentiation are to be identified and analysed – whereby the emphasis is on the 
analysis of the expression of genes for G protein-coupled receptors. Strategies are likewise 
to be elaborated for the enrichment of differentiated heart cells.  
 
Two further projects (Approvals 41 and 45) reviewed during the reporting period look at the 
immunological properties of hES cells and cells derived from them. As the use of cells or 
tissue differentiated from hES cells may be of importance in the long term for allogenic 
transplantations in patients with degenerative diseases, studies on the immune status of hES 
cells and on the question whether and, if so, to what extent their immunogenicity is changed 
by differentiation, are an important research goal.   
 
The seventh project (Approval 41) looks at the expression of genes in hES cells whose 
products are of immunological relevance and which may undergo a possible change in 
expression during cardiac differentiation of hES cells. There are also plans to develop 
strategies to influence the immune response to hES cells and to cardiac cells derived from 
them. The immune response triggered following allogenic transplantation of hES cells and 
the cardiac cells derived from them are to be comprehensively analysed in the animal model. 
 




Studies with a similar goal are envisaged in the eleventh project (Approval 45). The initial 
focus here is on the targeted differentiation of hES cells into human haematopoietic stem 
cells and the characterisation of their properties, viability and immunogenicity. The 
development of methods to reduce the immunogenicity of hES cells and haematopoietic 
stem cells manufactured from them as well as the analysis of their rejection behaviour after 
transplantation in suitable mouse models are further goals of the project. All studies in hES 
cells are to be conducted by way of comparison in hiPS cells, too. 
 
The eighth project (Approval 42) aims to optimise the protocols for the cultivation and 
effective cardiac differentiation of hES cells. It aims, more particularly, to monitor and 
quantify the influence of growth factors and specific molecules on the cardiac differentiation 
of hES cells. Furthermore, there are plans to establish and optimise differentiation in 
conjunction with miniaturised bioreactors under the influence of small molecules. The work 
also entails comparative studies of the cardiac differentiation of hES cells and hiPS cells. 
 
Project 9 (Approval 43) addresses the possible influence of specific transposable elements 
(long interspersed nuclear element-1, Line-1, L1) on the genetic stability of various hES cell 
lines. It aims to elucidate whether and on what scale hES cells produce the gene products 
needed for retrotransposition and whether the retrotransposition rate of L1 elements in hES 
cells changes in the course of differentiation into liver, lung and blood cells. Furthermore, it 
aims to examine whether the frequency of retrotransposition increases during the long-term 
cultivation of hES cells and whether the integration of mobilised retrotransposons tends to 
occur at preferred sites in the genome of hES cells. Studies are to be conducted in 
comparison to hiPS cells.  
 
The tenth project (Approval 44) focuses on the use and optimisation of novel techniques, so-
called microfluid systems, for the cultivation and differentiation of hES cells. It seeks to 
examine the influence of various carrier materials, media and so-called small molecules on 
the growth and properties of hES cells and on their differentiation into cardiac and hepatic 
cells. Based on the evaluation of miniaturised cultivation systems, automated cultivation 
methods and encapsulation conditions for the cultivation and differentiation of hES cells, 
reproducible, standardisable and, where appropriate, xenogenous-free cultivation methods 
are to be developed that can also be applied to hiPS cells. The work is part of the EU project 
“High Yield and Performance Stem Cell Lab” (HYPERLAB). It is conducted with other 
partners from abroad and with Cologne University (see Approval 42).  
 
Cultivation methods in bioreactors also play a role in Project 12 (Approval 46). Here the goal 
is to develop a pancreatic differentiation model for the in vitro reconstruction of islets of 
Langerhans with their insulin-producing cells. Via cells of the definitive entoderm and in co-
cultivation with various human cell types, hES cells are to be differentiated into mature 
pancreatic beta cells. To this end, three-dimensional co-cultivation systems and miniaturised 
bioreactors are to be used. The functionality of the differentiated cells both in vitro and after 
transplantation in diabetic mouse models are to be examined. Furthermore, there are plans 
for studies on the effects of various active ingredients, used to treat diabetes, on the 
pancreatic cells derived from hES cells. One major focus of the work is a direct comparison 
of hiPS cells with hES cells in the differentiation into functional pancreatic cells. Thereby 
hiPS cells from patients with various forms of diabetes are also to be generated with a view 
to using them to analyse the mechanisms of disease onset.  
 
The thirteenth project (Approval 47) looks at the role of the human Tcl1a oncogene (T-cell 
leukaemia/lymphoma 1a), in maintaining the pluripotency of hES cells. Following the 
inhibition of expression and after overexpression of the Tcl1a gene in hES cells, the 
phenotype of the resulting cells is to be comprehensively examined. There are likewise plans 
to identify and characterise the interaction partners of the Tcl1a protein in undifferentiated 
hES cells. 
 




The fourteenth project (Approval 48) aims to help to improve understanding of the neuronal 
differentiation of hES cells into cell types of the peripheral nervous system which are 
responsible for the perception and transmission of pain stimuli. The focus is on the 
establishment of conditions under which sub-populations of somatosensory neurons that 
have differentiated from hES cells, can be harnessed, cultivated and propagated if possible 
in pure form. The work also aims to help create the foundations for new in vitro cell 
cultivation models in order to examine cellular processes of pain reception and transduction, 
to analyse the effect of analgesic substances on neuronal cells and, where appropriate, to 
identify new analgesic substances. The methods developed in the project are to be 
transferred to hiPS cells, too.  
 
Project 15 (Approval 49) concentrates on the generation of cells from the human retina. 
Using three-dimensional cultivation systems protocols are to be developed and optimised 
that make possible the differentiation of hES cells into cells of the retinal pigment epithelium 
(RPE) and the neural retina. By combining both retinal cell types, the interaction is to be 
studied between cells in retina differentiation in vitro. Transplantation in the sub-retinal space 
of mice and in mouse models for retina degeneration are to be undertaken in order to 
examine their survival, their integration in recipient tissue and their functionality. Studies on 
the question whether hiPS cells and hES cells have a comparable potential for differentiation 
into retinal cells are planned, too.  
 
Further information on the content of the projects supported by ZES and approved by RKI 
can be accessed in the RKI register 
(http://www.rki.de/DE/Content/Gesund/Stammzellen/Register/register__node.html). The main 
ZES arguments concerning the superior interest of the research projects, their sufficient 
preliminary clarification and the need to use hES cells have been taken over into the 
assessment of the research projects by RKI.   
 
In its work now spanning seven years, ZES has deliberated on a total of 52 applications for 
the import and/or use of hES cells. In addition, three applications for extensions to already 
approved projects were reviewed. In total, 55 opinions were handed down to RKI, 53 of the 
votes were positive. All the projects supported by ZES, aside from one project, were 
approved by RKI. In the case of the one project that has not been approved up to now, the 
applicant requested the temporary suspension of the procedure. In Germany 36 research 
groups in 32 institutions are currently engaged in research involving hES cells. Experimental 
findings from the approved research projects of eight groups have been presented in 25 
scientific publications.  
 
During the reporting period the Committee definitively reviewed ten applications from 
research groups, that had not previously worked with hES cells as well as five applications 
from groups that had already been granted corresponding approval in the past. In the run-up 
to the decision on all these applications, for which in some cases ZES went back to the 



















































Fig. 1: Number of applications reviewed by ZES (grey columns) and approved by RKI (black columns) pursuant to 
StZG in the respective calendar year. Extension applications, on which ZES also handed down an 





Outlook and final comments 
 
The number of applications for the import and/or use of hES cells has risen markedly since 
2009. In 2008 and 2009 just as many applications were examined and reviewed as in the 
previous five years since the entry into force of StZG (see Fig. 1). This can be attributed, 
amongst other things, to the research in hiPS cells that only began with a description of 
these cells at the end of 2007 and for which hES cells are required in many cases for 
comparative purposes.  
 
During the reporting period the number of human embryonic stem cell lines, whose import 
and use was approved by RKI, has also risen. Whereas between 2002 and the end of 2008 
approvals were given for the import and use of 20 of the 21 lines in the NIH register available 
at that time, approvals have since been given to 23 “new” hES cell lines which were 
produced between 1 January 2002 and 1 May 2007. They are the following lines: HUES1, 
HUES2, HUES4, HUES6, HUES7, HUES8 and HUES10 of Harvard University (USA), the 
lines Shef-1, Shef-2 and Shef-3 of Sheffield University (England), the lines HS181, HS401 
and HS415 of the Karolinska Institute (Sweden), the lines NCL3 and NCL4 of the Newcastle 
Fertility Centre (England), the lines SA121, SA167, SA181, SA348 and SA461 of the 
company Cellartis AB (Sweden) and the lines KhES-1, KhES-2 and KhES-3 of Kyoto 
University (Japan). The fact that applications were made for several hES cell lines for the 
conduct of various projects can be attributed, amongst other things, to the fact that the 
properties of various hES cell lines are not exactly the same. In many cases it can only be 
determined during the project which lines are suitable for specific purposes like, for instance, 
differentiation into a specific cell type.  
 
It should be noted that various applications point out that studies in animal cells in the run up 
to work with hES cells only have limited meaning for the study question. For instance, murine 
embryonic stem cells in particular differ in some cases markedly from hES cells, e.g. 
concerning the molecular mechanisms of their pluripotency or their immunological properties. 




Hence concrete project contents, that are to be elucidated using hES cells, cannot be 
clarified in a preliminary manner in many cases using animal embryonic stem cells. 
Furthermore, research on hES cells is growing faster than ever on the international level (in 
2009 more than 400 original papers were published). Hence, planned questions, including 
specific methodological procedures, have sometimes already been examined abroad in hES 
cells. This means that further preliminary clarification in animal cells does not always make 
sense. 
 
What is noticeable recently is that more projects are being conducted involving parallel 
studies with hiPS cells and hES cells. hES cells are deemed to have a high potential in basic 
research, in research into the pathogenicity of disease (as a cell model), in active ingredient 
and toxicity research and, in the longer term, in regenerative medicine. One goal of the 
majority of scientific projects reviewed during the reporting period is to examine the question 
whether and, if so, on what scale hiPS cells and hES cells are in fact the same. So far the 
mechanisms of reprogramming are still largely unelucidated. It is unclear whether the 
reprogramming of various human somatic cells (e.g. fibroblasts, cells of the umbilical cord 
blood, neuronal precursor cells, patients’ cells) using various methods (for instance 
transduction of genes for various transcription factors with the help of various vectors, use of 
specific small molecules, treatment with a protein cocktail of various transcription factors) 
leads to pluripotent cells that have comparable properties to hES cells. This means that in 
research activities involving hiPS cells there is still a need for comparison with hES cells. 
Hence, the growing body of research with hiPS cells leads to the increased use of hES cells 
as, without comparative studies, the original properties of hES cells, like pluripotency and 
differentiatability, cannot be compared with the corresponding experimentally induced 
properties of somatic cells. However still a significant number of projects focuses on the 
study of a scientific question in hES cells which – only after successful examination in these 
hES cells – can then be transferred in part to hiPS cells, too. Based on the experience of 
ZES in the previous reporting period, hES cells are not just used for comparative purposes – 
as frequently stressed in the public debate – but also continue to be a separate subject of 
research.  
 
A number of the applications reviewed by ZES also continue to pursue the goal of possible 
later cell and tissue therapies based on hES cells. However, the use of hES cells for 
purposes other than research is still not permitted in Germany. ZES has already drawn 
attention to this problem in earlier reports. 
 
It has already been mentioned that many of the projects reviewed by ZES in the reporting 
period envisage comparative research of hES cells and hiPS cells. In its opinions on these 
projects ZES points out that a vote has to be sought from the Ethics Committee in charge of 
the responsible research institution if human material is to be harvested to produce hiPS 
cells from patients or volunteers within the framework of the project.  
 
The remarkable increase in research projects with hiPS cells during the reporting period is 
also due to the fact that these cells are exposed to fewer public controversies than hES cells. 
When frequent use is made in public of the term “ethically safe” hiPS cells, this does, 
however, suggest that the handling of hES cells was in itself a matter of concern from the 
ethical angle. ZES, however, assumes in the review of the research projects within the 
intendment of the law that research with hES cells is ethically acceptable. 
 
The Seventh Report was unanimously approved at the 49th ordinary meeting of ZES on 14 
December 2009. 
